S-1 + concurrent chemoradiotherapy

S-1 + concurrent chemoradiotherapy (CCRT) is a combination therapy used primarily in the treatment of various solid tumors, especially gastrointestinal and head and neck cancers. S-1 is an oral fluoropyrimidine anticancer drug composed of three components: tegafur (a prodrug of 5-fluorouracil), gimeracil (a dihydropyrimidine dehydrogenase inhibitor that increases 5-FU levels by inhibiting its degradation), and oteracil potassium (which reduces gastrointestinal toxicity by inhibiting phosphorylation of 5-FU in normal digestive tissues)[2][5]. When combined with radiotherapy as part of CCRT regimens, this approach aims to maximize antitumor efficacy while minimizing toxicity compared to traditional cisplatin-based regimens[1][3]. The combination has demonstrated efficacy and tolerability in several cancer types including esophageal squamous cell carcinoma, nasopharyngeal carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, biliary tract cancer, non-small cell lung cancer, and head and neck cancers[2][3][5]. The oral administration route offers convenience over intravenous chemotherapy.

Brand names

TeysunoTS-1TS1TS 1

Other names

tegafur/gimeracil/oteracil + CCRTS-1 plus CCRTS1 plus CCRTS 1 plus CCRTS-1 with concurrent chemoradiotherapyS1 with concurrent chemoradiotherapyS 1 with concurrent chemoradiotherapy